Loading
Virus-based Gene Therapy Research / RNA Interference and Gene Delivery / CRISPR and Genetic Engineering · Journal article
International Journal of Multidisciplinary and Innovative Research · August 18, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes current analytical, manufacturing, and safety frameworks for viral vector-based gene therapies—primarily rAAV, lentiviruses, and adenoviruses—intended to inform both laboratory developers and regulatory bodies. The article does not present new empirical data or clinical trial results, but rather integrates existing knowledge on quality attributes, assay limitations, and methods for detecting off-target genomic effects and replication-competent variants.
Journal article. Viral vector-based gene therapies (rAAV, lentiviruses, adenoviruses) in development and clinical application; no patient population studied..
Viral vectors are presented as the backbone delivery platform for CRISPR-Cas and other genome-editing machinery into target cells. Core quality attributes for characterization include genome titer, physical-to-infectious particle ratios, empty versus full capsid discrimination, and quantification of residual host-cell proteins and nucleic acids. Methods for detecting unintended double-strand breaks at off-target sites, structural rearrangements, and replication-competent viral variants are examined for reliability and practical limitations.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This framework is intended to guide laboratory and regulatory teams in establishing harmonized, multi-layered quality control systems for vector-based gene therapies. Clinicians and manufacturers should use this review to understand current best practices and limitations in analytical characterization, but note that it does not provide efficacy or safety data from clinical trials.
A comprehensive review of analytical and quality control frameworks for viral vector-based gene therapies, intended to inform laboratory and regulatory practice without presenting primary clinical trial data.
This framework is intended to guide laboratory and regulatory teams in establishing harmonized, multi-layered quality control systems for vector-based gene therapies. Clinicians and manufacturers should use this review to understand current best practices and limitations in analytical characterization, but note that it does not provide efficacy or safety data from clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Viral vectors have become the backbone of delivery strategies in modern gene therapy, offering biologically robust means of transporting therapeutic transgenes and genome-editing machinery, most notably CRISPR-Cas nuclease systems, into target cells. Moving these intricate macromolecular assemblies from bench-scale research into human clinical application, however, is far from straightforward: it raises substantial analytical, manufacturing, and safety questions that cannot be resolved through conventional characterization alone. Meeting international regulatory expectations demands the establishment of harmonized, multi-layered quality control systems spanning every stage of vector production. This review takes a critical look at the analytical approaches currently used to characterize viral delivery platforms, with particular attention to recombinant adeno-associated viruses (rAAV), lentiviruses, and adenoviruses. We examine the core quality attributes that define these products—genome titer determination, ratios of physical to infectious particles, discrimination between empty and full capsids, and quantification of residual host-cell proteins and host-derived nucleic acids—and consider how well existing assays actually capture these properties in practice. Beyond product characterization, we turn to nuclease-associated safety concerns, reviewing the methods available for detecting unintended double-strand breaks at off-target sites, structural rearrangements within the genome, and the emergence of replication-competent viral variants. By weighing what current technologies can reliably achieve against their practical limitations, this article aims to provide a working framework for verifying the potency, genomic integrity, and clinical safety of vector-based gene therapies—one intended to be useful both to laboratories developing these products and to those responsible for regulating them.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.